Paul-Ehrlich-Institut
Federal · Germany · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
Paul-ehrlich-str. 51-59, Dreieich, Hesse...Phone Number
+49 6103770Website
www.pei.deRevenue
$24.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
2
1
1
About Paul-Ehrlich-Institut
The Paul-Ehrlich-Institut is a federal institute under the Federal Ministry of Health that promotes the quality, efficacy, and safety of biomedical drugs through research and testing. It specializes in various products including vaccines, antibodies, blood products, and gene therapies. The institute serves a wide range of clients, including pharmaceutical companies, healthcare professionals, and regulatory bodies, both nationally and internationally. Additionally, it is involved in pharmacovigilance and provides consultation for clinical trials and drug approvals.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Paul-Ehrlich-Institut your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Paul-Ehrlich-Institut has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Paul-Ehrlich-Institut launches new products
Paul-Ehrlich-Institut, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Paul-Ehrlich-Institut recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Paul-Ehrlich-Institut is spiking on competitors!
Click to see if Paul-Ehrlich-Institut had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Paul-Ehrlich-Institut
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Paul-Ehrlich-Institut has new funding data
Recommended Actions
Find VP level buyers at Paul-Ehrlich-Institut
Find 3 more new buyers
Company Profile Activity
Activity Insights
Paul-Ehrlich-Institut is experiencing very low activity levels compared to other companies in the Government sector.
What does this means?
Paul-Ehrlich-Institut is drawing exceptional interest within the Government industry, suggesting notable developments or strong market momentum, learn more about Paul-Ehrlich-Institut.
Paul-Ehrlich-Institut Tech Stack
A closer look at the technologies used by Paul-Ehrlich-Institut
Paul-Ehrlich-Institut News & Media
BiondVax receives supportive Scientific Advice from the Paul Ehrlich Institute (PEI) for COVID-19 NanoAb development plans including first-in-human Phase 1/2a safety and efficacy clinical trial
PEI supports BiondVax's plan for first-in-human clinical trial to be conducted in patients as a combined Phase 1/2a, testing both safety and efficacy, thereby shortening BiondVax's clinical development timelines for its first NanoAb product, a COVID-19 therapeutic; PEI is a part of the...Valo Therapeutics Announces Clinical Trial Application Submission for German Phase I Oncology Clinical Trial of PeptiCRAd-1 with Pembrolizumab
HELSINKI, July 13, 2021 /PRNewswire/ -- Valo Therapeutics Limited (Valo Tx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced it has submitted a clinical trial application (CTA) to the German Regulatory Agency, The Paul Ehrlich...Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel
HAIFA, Israel, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today that it has received approval from the Israeli Ministry of Health to commence patient enrollment in Israel for the Company’s COVID-19 Phase II clinical trial, under the protocol that was approved by the Paul Ehrlich Institute (PEI), Germany’s regulatory agency. A total of 40Pluristem Expands its COVID-19 Program to Europe, Receives PEI Clearance to Commence Phase II Study in Germany
HAIFA, Israel, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today that Germany’s health regulatory agency, the Paul Ehrlich Institute (PEI), has cleared the Company’s Phase II clinical protocol for its study titled, “A Randomized, Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Inj
Read more news
Top Federal Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Paul-Ehrlich-Institut
Sign Up For FreeTo access detailed company insights
The Paul-Ehrlich-Institut is a federal institute under the Federal Ministry of Health that promotes the quality, efficacy, and safety of biomedical drugs through research and testing. It specializes in various products including vaccines, antibodies, blood products, and gene therapies. The institute serves a wide range of clients, including pharmac... Read More
